These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37093125)

  • 1. Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys.
    Shen L; Wong A; Oneda S; Curtis BR; Schroeder J; Zanardi T; Engelhardt JA; Henry SP; Narayanan P
    Nucleic Acid Ther; 2023 Jun; 33(3):209-225. PubMed ID: 37093125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
    Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
    Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
    Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
    Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome sequence of Macaca fascicularis: liver tissue.
    Seo EH; Kim JH; Kim DH; Oh JH; Kim SY
    BMC Genom Data; 2023 Feb; 24(1):6. PubMed ID: 36788535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates.
    Slingsby MHL; Vijey P; Tsai IT; Roweth H; Couldwell G; Wilkie AR; Gaus H; Goolsby JM; Okazaki R; Terkovich BE; Semple JW; Thon JN; Henry SP; Narayanan P; Italiano JE
    Haematologica; 2022 Feb; 107(2):519-531. PubMed ID: 33567808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
    Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
    J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotides.
    Harada K; Furukawa H; Kohara H; Nishimura K; Komori H; Okai Y; Arai Y; Yamamoto Y; Yamamoto K; Imanishi A; Shinozawa T
    Toxicol In Vitro; 2023 Jun; 89():105569. PubMed ID: 36801361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.
    Crooke ST; Baker BF; Witztum JL; Kwoh TJ; Pham NC; Salgado N; McEvoy BW; Cheng W; Hughes SG; Bhanot S; Geary RS
    Nucleic Acid Ther; 2017 Jun; 27(3):121-129. PubMed ID: 28145801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.
    Younis HS; Crosby J; Huh JI; Lee HS; Rime S; Monia B; Henry SP
    Blood; 2012 Mar; 119(10):2401-8. PubMed ID: 22246038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
    Crooke ST; Baker BF; Kwoh TJ; Cheng W; Schulz DJ; Xia S; Salgado N; Bui HH; Hart CE; Burel SA; Younis HS; Geary RS; Henry SP; Bhanot S
    Mol Ther; 2016 Oct; 24(10):1771-1782. PubMed ID: 27357629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
    Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
    Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
    Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
    Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of idiopathic thrombocytopenic purpura patients with antiglycoprotein IIb/IIIa or Ib autoantibodies.
    Nomura S; Yanabu M; Soga T; Kido H; Fukuroi T; Yamaguchi K; Nagata H; Kokawa T; Yasunaga K
    Acta Haematol; 1991; 86(1):25-30. PubMed ID: 1950358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.